| human | Q5 |
| P11496 | CiNii Research ID | 1140282266729600512 |
| P1280 | CONOR.SI ID | 92935523 |
| P6178 | Dimensions author ID | 0756560051.29 |
| P269 | IdRef ID | 23459764X |
| P244 | Library of Congress authority ID | n85817090 |
| P271 | NACSIS-CAT author ID | DA03017134 |
| P8189 | National Library of Israel J9U ID | 987007427746005171 |
| P2038 | ResearchGate profile ID | Helen-Pettinati |
| P214 | VIAF ID | 23609175 |
| P1412 | languages spoken, written or signed | English | Q1860 |
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | female | Q6581072 |
| Q36090479 | A double blind, placebo controlled trial of modafinil for the treatment of cocaine dependence without co-morbid alcohol dependence |
| Q36642532 | A double blind, placebo-controlled trial that combines disulfiram and naltrexone for treating co-occurring cocaine and alcohol dependence |
| Q34479286 | A double-blind, placebo-controlled pilot trial of acamprosate for the treatment of cocaine dependence |
| Q35354770 | A double-blind, placebo-controlled pilot trial of quetiapine for the treatment of Type A and Type B alcoholism |
| Q42971800 | A double-blind, placebo-controlled study with quetiapine as adjunct therapy with lithium or divalproex in bipolar I patients with coexisting alcohol dependence |
| Q30417813 | A double-blind, placebo-controlled trial assessing the efficacy of levetiracetam extended-release in very heavy drinking alcohol-dependent patients |
| Q30412161 | A double-blind, placebo-controlled trial assessing the efficacy of varenicline tartrate for alcohol dependence |
| Q35062922 | A double-blind, placebo-controlled trial combining sertraline and naltrexone for treating co-occurring depression and alcohol dependence |
| Q48700054 | A double-blind, placebo-controlled trial of amantadine, propranolol, and their combination for the treatment of cocaine dependence in patients with severe cocaine withdrawal symptoms |
| Q34365126 | A double-blind, placebo-controlled trial of modafinil for cocaine dependence |
| Q83538757 | A double-blind, placebo-controlled trial of modafinil for cocaine dependence |
| Q34653718 | A double-blind, placebo-controlled trial of topiramate for the treatment of comorbid cocaine and alcohol dependence |
| Q30422068 | A double-blind, placebo-controlled trial to assess the efficacy of quetiapine fumarate XR in very heavy-drinking alcohol-dependent patients |
| Q35088135 | A double-blind, randomized trial of sertraline for alcohol dependence: moderation by age of onset [corrected] and 5-hydroxytryptamine transporter-linked promoter region genotype |
| Q44341917 | A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients |
| Q44962403 | A multi-site dose ranging study of nalmefene in the treatment of alcohol dependence |
| Q52305615 | A pilot trial of injectable, extended-release naltrexone for the treatment of co-occurring cocaine and alcohol dependence. |
| Q44448282 | A pilot trial of olanzapine for the treatment of cocaine dependence |
| Q34649737 | A pilot trial of topiramate for the treatment of cocaine dependence |
| Q45921368 | A placebo-controlled evaluation of vasopressin for ECT-induced memory impairment. |
| Q37267741 | A placebo-controlled randomized clinical trial of naltrexone in the context of different levels of psychosocial intervention |
| Q41199873 | A risk-benefit assessment of naltrexone in the treatment of alcohol dependence |
| Q46751109 | A structured approach to medical management: a psychosocial intervention to support pharmacotherapy in the treatment of alcohol dependence. |
| Q44213301 | Alcoholism treatment adherence: older age predicts better adherence and drinking outcomes |
| Q44594245 | Alleles of a functional serotonin transporter promoter polymorphism are associated with major depression in alcoholics |
| Q41295465 | An application of an MMPI classification system for predicting outcome in a small clinical sample of alcoholics |
| Q24645469 | An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study |
| Q44579557 | An examination of potential sex and race effects in a study of continuing care for alcohol- and cocaine-dependent patients |
| Q36868625 | An intervention for treating alcohol dependence: relating elements of Medical Management to patient outcomes with implications for primary care |
| Q35958316 | Antidepressant treatment of co-occurring depression and alcohol dependence |
| Q52205743 | Assessing depression in evaluating memory impairment. |
| Q34980182 | Association analysis between polymorphisms in the conserved dopamine neurotrophic factor (CDNF) gene and cocaine dependence |
| Q43156338 | Association analysis between polymorphisms in the dopamine D2 receptor (DRD2) and dopamine transporter (DAT1) genes with cocaine dependence |
| Q34019614 | Association analysis between polymorphisms in the dopamine D3 receptor (DRD3) gene and cocaine dependence |
| Q36973407 | Association between the catechol-O-methyltransferase Val158Met polymorphism and cocaine dependence |
| Q44860128 | Association of a long-chain fatty acid-CoA ligase 4 gene polymorphism with depression and with enhanced niacin-induced dermal erythema |
| Q77902436 | Benzodiazepines and Electroconvulsive Therapy |
| Q68627261 | Benzodiazepines and unilateral ECT |
| Q44190211 | Carbohydrate-deficient transferrin levels reflect heavy drinking in alcohol-dependent women seeking treatment |
| Q50958100 | Carbohydrate-deficient transferrin: an investigative biochemical marker of heavy alcohol consumption. |
| Q36431241 | Case-control association analysis of polymorphisms in the δ-opioid receptor, OPRD1, with cocaine and opioid addicted populations |
| Q36881320 | Case-control association study of WLS variants in opioid and cocaine addicted populations. |
| Q36915555 | Choosing an Electroconvulsive Therapy Device |
| Q46751103 | Choosing pharmacotherapies for the COMBINE Study--process and procedures: an investigational approach to combination pharmacotherapy for the treatment of alcohol dependence. |
| Q34565568 | Choosing the right medication for the treatment of alcoholism |
| Q34592779 | Clinical Review of Medcraft Corporation's New Brief-Pulse ECT Device. |
| Q50848559 | Clinical correlations with carbohydrate-deficient transferrin levels in women with alcoholism. |
| Q44758246 | Cocaine dependence severity predicts outcome in outpatient detoxification from cocaine and alcohol |
| Q40663350 | Cocaine withdrawal severity and urine toxicology results from treatment entry predict outcome in medication trials for cocaine dependence |
| Q37063473 | Cocaine withdrawal symptoms identify "Type B" cocaine-dependent patients. |
| Q71254246 | Cognitive functioning in depressed geriatric patients with a history of ECT |
| Q37442751 | Combined effects of alcohol and hepatitis C: a secondary analysis of alcohol use biomarkers and high-risk behaviors from two medication trials for alcohol dependence |
| Q38407349 | Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. |
| Q44815119 | Comparing bilateral to unilateral electroconvulsive therapy in a randomized study with EEG monitoring |
| Q44150342 | Concurrent cocaine withdrawal alters alcohol withdrawal symptoms |
| Q34514200 | Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial |
| Q27014938 | Current status of co-occurring mood and substance use disorders: a new therapeutic target |
| Q52093278 | Dexamethasone in electroconvulsive therapy: efficacy for depression and post-ECT amnesia. |
| Q53889190 | Diagnosing personality disorders in substance abusers. |
| Q51760163 | Differential anxiety symptoms in cocaine vs. alcoholic patients. |
| Q52210037 | Differential memory complaints after bilateral and unilateral ECT. |
| Q68778707 | Distinguishing the role of eating disturbance from depression in the sex role self-perceptions of anorexic and bulimic inpatients |
| Q45243721 | Do patient characteristics and initial progress in treatment moderate the effectiveness of telephone-based continuing care for substance use disorders? |
| Q43555122 | Double-blind clinical trial of sertraline treatment for alcohol dependence |
| Q45781979 | Early treatment response in alcohol dependence with extended-release naltrexone. |
| Q34291872 | Effect of extended-release naltrexone (XR-NTX) on quality of life in alcohol-dependent patients |
| Q37060490 | Effects of alcoholism typology on response to naltrexone in the COMBINE study |
| Q46423593 | Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial |
| Q45270626 | Efficacy of extended-release naltrexone in patients with relatively higher severity of alcohol dependence |
| Q68864289 | Evidence for less improvement in depression in patients taking benzodiazepines during unilateral ECT |
| Q55663366 | Extended-Release Injectable Naltrexone (XR-NTX) With Intensive Psychosocial Therapy for Amphetamine-Dependent Persons Seeking Treatment: A Placebo-Controlled Trial. |
| Q71468152 | Four year MMPI changes in abstinent and drinking alcoholics |
| Q35571722 | Further evidence for association of polymorphisms in the CNR1 gene with cocaine addiction: confirmation in an independent sample and meta-analysis |
| Q58298521 | Gender and Psychiatric Comorbidity: Impact on Clinical Presentation of Alcohol Dependence |
| Q34622414 | Gender differences in alcohol treatment: an analysis of outcome from the COMBINE study |
| Q50912576 | Gender differences in comorbidly depressed alcohol-dependent outpatients. |
| Q37133906 | Gender differences in predictors of treatment attrition with high dose naltrexone in cocaine and alcohol dependence |
| Q45061459 | Gender differences in response to sertraline pharmacotherapy in Type A alcohol dependence |
| Q37011196 | Gender differences with high-dose naltrexone in patients with co-occurring cocaine and alcohol dependence |
| Q47988659 | Genetic association analyses of PDYN polymorphisms with heroin and cocaine addiction. |
| Q36828742 | Genetic variants in the cocaine- and amphetamine-regulated transcript gene (CARTPT) and cocaine dependence |
| Q67950776 | HIV-risk behaviors among a middle class population: a preliminary investigation among adolescent vs. adult substance users |
| Q69090577 | Hypnosis in the treatment of anorexic and bulimic patients |
| Q43689020 | Hypnotizability in patients with anorexia nervosa and bulimia |
| Q52060264 | Hypnotizability of psychiatric inpatients according to two different scales. |
| Q73692488 | Improving naltrexone response: an intervention for medical practitioners to enhance medication compliance in alcohol dependent patients |
| Q67950709 | Impulsivity and substance abusers: changes with treatment and recovery |
| Q51720368 | Incidence of personality disorders in cocaine vs. alcohol-dependent females. |
| Q77901380 | Increased Incidence of Missed Seizures During ECT in the Elderly Male |
| Q77901239 | Initial Impression of Two New Brief-Pulse Electroconvulsive Therapy Machines |
| Q37311915 | Initiating acamprosate within-detoxification versus post-detoxification in the treatment of alcohol dependence |
| Q58118159 | Inpatient Alcohol Treatment in a Private Healthcare Setting: Which Patients Benefit and at What Cost? |
| Q40855535 | Inpatient vs outpatient treatment for substance dependence revisited |
| Q48414006 | Letter to the editor in regard to Timko, DeBenedetti, Moos, and Moos (2006): "Predictors of 16-year mortality among individuals initiating help-seeking for an alcoholic use disorder". |
| Q70406727 | Long term outcome in working and homemaking alcoholic women |
| Q30399592 | Long-term opioid blockade and hedonic response: preliminary data from two open-label extension studies with extended-release naltrexone |
| Q34330604 | Low frequency genetic variants in the μ-opioid receptor (OPRM1) affect risk for addiction to heroin and cocaine. |
| Q58957991 | Low use of neuroleptic drugs in the treatment of psychotic major depression |
| Q70481616 | Measuring hypnotizability in psychotic patients |
| Q52090507 | Memory complaints in depressed geriatric inpatients. |
| Q52211235 | Memory self-ratings before and after electroconvulsive therapy: depression-versus ECT induced. |
| Q77901400 | Meta-Analysis of Effects of Electrode Placements |
| Q34592682 | Meta-Analytical Approach to Reconciling Discrepancies in Efficacy between Bilateral and Unilateral Electroconvulsive Therapy. |
| Q70083920 | Missed and brief seizures during ECT: differential response between unilateral and bilateral electrode placement |
| Q37492566 | Neuronal calcium sensor-1 and cocaine addiction: a genetic association study in African-Americans and European Americans |
| Q34344220 | New pharmacotherapies for treating the neurobiology of alcohol and drug addiction |
| Q37185125 | OPRM1 Asn40Asp predicts response to naltrexone treatment: a haplotype-based approach |
| Q28376516 | Open trials as a method of prioritizing medications for inclusion in controlled trials for cocaine dependence |
| Q44592564 | Patient Attitudes toward Treatment Predict Attendance in Clinical Pharmacotherapy Trials of Alcohol and Drug Treatment |
| Q72598534 | Patient attitudes toward electroconvulsive therapy |
| Q52108274 | Posthypnotic amnesia: evaluation of selective recall of successful experiences |
| Q43752726 | Predicting treatment response to naltrexone: the influence of craving and family history |
| Q37184684 | Predictors of treatment outcome in outpatient cocaine and alcohol dependence treatment |
| Q44718662 | Priority actions to improve the care of persons with co-occurring substance abuse and other mental disorders: a call to action |
| Q52277465 | Psychometric properties of the Penn Alcohol Craving Scale. |
| Q36858291 | Reduction in heavy drinking as a treatment outcome in alcohol dependence |
| Q44139859 | Relation of depression diagnoses to 2-year outcomes in cocaine-dependent patients in a randomized continuing care study |
| Q36952204 | Relationship between medication adherence and treatment outcomes: the COMBINE study. |
| Q58280664 | Reliability and Validity of the Aggregate Method of Determining Number of Cigarettes Smoked Per Day |
| Q77533524 | Reliability and validity of the aggregate method of determining number of cigarettes smoked per day |
| Q58958047 | Resistance to antidepressant medications and short-term clinical response to ECT |
| Q49119841 | Restricted use of success cues in retrieval during posthypnotic amnesia |
| Q37400844 | Results from a pilot clinical trial of varenicline for the treatment of alcohol dependence |
| Q35685676 | Results of an initial clinical trial of varenicline for the treatment of cocaine dependence |
| Q71862703 | Ritanserin in the treatment of alcohol dependence--a multi-center clinical trial. Ritanserin Study Group |
| Q52292587 | Role of serotonin and serotonin-selective pharmacotherapy in alcohol dependence. |
| Q74103608 | Sertraline treatment for alcohol dependence: interactive effects of medication and alcoholic subtype |
| Q46896020 | Sertraline treatment of co-occurring alcohol dependence and major depression |
| Q72117645 | Speed of ECT? |
| Q34156468 | The COMBINE Study-: An Overview of the Largest Pharmacotherapy Study to Date for Treating Alcohol Dependence. |
| Q51700999 | The Fifth Edition of the Addiction Severity Index |
| Q58177502 | The Relationship of Axis II Personality Disorders to Other Known Predictors of Addiction Treatment Outcome |
| Q58258894 | The Role of Female Occupation in Severity of Alcohol-Related Problems |
| Q51394434 | The combination of phentermine and fenfluramine reduced cocaine withdrawal symptoms in an open trial. |
| Q71515314 | The development of the Comprehensive Addiction Severity Index for Adolescents (CASI-A). An interview for assessing multiple problems of adolescents |
| Q33579769 | The dopamine receptor D2 (DRD2) SNP rs1076560 is associated with opioid addiction |
| Q45256275 | The effectiveness of telephone-based continuing care for alcohol and cocaine dependence: 24-month outcomes |
| Q45197005 | The effectiveness of telephone-based continuing care in the clinical management of alcohol and cocaine use disorders: 12-month outcomes |
| Q28369822 | The effects of naltrexone on alcohol and cocaine use in dually addicted patients |
| Q70458383 | The natural history of alcoholism over four years after treatment |
| Q51565194 | The natural history of outpatient alcohol and drug abuse treatment in a private healthcare setting. |
| Q36479984 | The status of disulfiram: a half of a century later |
| Q36655825 | The status of naltrexone in the treatment of alcohol dependence: specific effects on heavy drinking |
| Q35085731 | The status of serotonin-selective pharmacotherapy in the treatment of alcohol dependence |
| Q37011213 | The therapeutic alliance in medical-based interventions impacts outcome in treating alcohol dependence |
| Q34390021 | The use of selective serotonin reuptake inhibitors in treating alcoholic subtypes |
| Q34536749 | Treatment outcomes in type A and B alcohol dependence 6 months after serotonergic pharmacotherapy |
| Q41199444 | Use of serotonin selective pharmacotherapy in the treatment of alcohol dependence |
| Q43940334 | Using acquired knowledge and new technologies in alcoholism treatment trials |
| Q52118458 | Vasopressin for ECT-induced memory impairment: a placebo-controlled comparison. |
Search more.